BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,089,013 | -21.7% | 55,350 | -5.5% | 0.01% | -20.0% |
| Q2 2023 | $2,669,302 | +14.1% | 58,584 | +1.5% | 0.01% | +11.1% |
| Q1 2023 | $2,339,824 | -60.8% | 57,699 | -50.8% | 0.01% | -25.0% |
| Q4 2022 | $5,971,287 | +97.9% | 117,193 | +109.2% | 0.01% | -7.7% |
| Q3 2022 | $3,017,000 | -13.6% | 56,014 | -0.4% | 0.01% | -18.8% |
| Q2 2022 | $3,491,000 | -17.2% | 56,258 | +3.5% | 0.02% | -15.8% |
| Q1 2022 | $4,216,000 | -5.0% | 54,356 | +5.1% | 0.02% | 0.0% |
| Q4 2021 | $4,439,000 | +3.0% | 51,716 | -3.4% | 0.02% | 0.0% |
| Q3 2021 | $4,309,000 | -3.3% | 53,561 | -3.2% | 0.02% | -5.0% |
| Q2 2021 | $4,454,000 | -4.2% | 55,333 | +0.4% | 0.02% | 0.0% |
| Q1 2021 | $4,649,000 | -11.8% | 55,119 | -16.1% | 0.02% | -13.0% |
| Q4 2020 | $5,271,000 | +6.0% | 65,691 | +6.2% | 0.02% | -4.2% |
| Q3 2020 | $4,973,000 | -8.9% | 61,856 | -2.4% | 0.02% | -17.2% |
| Q2 2020 | $5,459,000 | -1.1% | 63,392 | -6.8% | 0.03% | -12.1% |
| Q1 2020 | $5,522,000 | +5.6% | 68,024 | +8.7% | 0.03% | +32.0% |
| Q4 2019 | $5,229,000 | -14.3% | 62,555 | -10.3% | 0.02% | -16.7% |
| Q3 2019 | $6,102,000 | +7.0% | 69,755 | +0.2% | 0.03% | 0.0% |
| Q2 2019 | $5,701,000 | -9.9% | 69,584 | -10.5% | 0.03% | -9.1% |
| Q1 2019 | $6,325,000 | +6.9% | 77,766 | -13.5% | 0.03% | -2.9% |
| Q4 2018 | $5,919,000 | -22.0% | 89,939 | -8.4% | 0.03% | -10.5% |
| Q3 2018 | $7,590,000 | -14.3% | 98,154 | -17.9% | 0.04% | -20.8% |
| Q2 2018 | $8,854,000 | +7.8% | 119,620 | -5.1% | 0.05% | +9.1% |
| Q1 2018 | $8,210,000 | -1.6% | 126,031 | -2.2% | 0.04% | 0.0% |
| Q4 2017 | $8,346,000 | +5.7% | 128,892 | +2.6% | 0.04% | +2.3% |
| Q3 2017 | $7,894,000 | -0.1% | 125,611 | -3.7% | 0.04% | -8.5% |
| Q2 2017 | $7,904,000 | +49.9% | 130,372 | +28.4% | 0.05% | +46.9% |
| Q1 2017 | $5,272,000 | +27.3% | 101,537 | +8.8% | 0.03% | +23.1% |
| Q4 2016 | $4,140,000 | -18.3% | 93,351 | -12.2% | 0.03% | -18.8% |
| Q3 2016 | $5,066,000 | +13.1% | 106,346 | +7.4% | 0.03% | +6.7% |
| Q2 2016 | $4,479,000 | +2.8% | 99,002 | -7.2% | 0.03% | +3.4% |
| Q1 2016 | $4,355,000 | +1.0% | 106,666 | -6.2% | 0.03% | 0.0% |
| Q4 2015 | $4,312,000 | +9.2% | 113,734 | -5.9% | 0.03% | +7.4% |
| Q3 2015 | $3,947,000 | -49.8% | 120,827 | +6.8% | 0.03% | -42.6% |
| Q2 2015 | $7,860,000 | -3.3% | 113,110 | -5.9% | 0.05% | -7.8% |
| Q1 2015 | $8,126,000 | -14.8% | 120,225 | -8.8% | 0.05% | -15.0% |
| Q4 2014 | $9,540,000 | +14.3% | 131,773 | +11.8% | 0.06% | +11.1% |
| Q3 2014 | $8,347,000 | +724.8% | 117,887 | +742.4% | 0.05% | +28.6% |
| Q2 2014 | $1,012,000 | -1.7% | 13,994 | 0.0% | 0.04% | -2.3% |
| Q1 2014 | $1,030,000 | +2.0% | 13,994 | -3.6% | 0.04% | +2.4% |
| Q4 2013 | $1,010,000 | +5.4% | 14,523 | -0.5% | 0.04% | -8.7% |
| Q3 2013 | $958,000 | -3.7% | 14,594 | +1.7% | 0.05% | -4.2% |
| Q2 2013 | $995,000 | – | 14,354 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |